Clene Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Clene Inc. (CLNN) on March 13, 2026. The filing reports the entry into a material definitive agreement regarding the third year of a National Institutes of Health (NIH) grant supporting an Expanded Access Program for CNM-Au8® treatment of amyotrophic lateral sclerosis (ALS).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is the value of the new subaward agreement:
- Year 3 Subaward Amount: Up to $8.0 million.
- Grant Period: September 1, 2025, to August 31, 2026.
- Prime Awardee: New York University (NYU).
Material Changes and Agreement Details
This filing represents a continuation of a four-year, $45.1 million NIH Grant awarded in October 2023. Previous subawards were executed with Columbia University for Year 1 ($7.3 million) and Year 2 ($8.0 million). The current agreement with NYU for Year 3 maintains the $8.0 million funding level.
- Payment Terms: Funds are disbursed via reimbursement based on monthly invoices submitted to NYU.
- Termination: Either party may terminate the agreement with 30 days' written notice.
- Intellectual Property: Clene retains ownership of Background IP developed prior to the subaward. No licenses are granted to NYU or the U.S. Government regarding this IP, and no proprietary data must be delivered until satisfactory confidentiality safeguards are agreed upon.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or a discussion of general business risks beyond the terms of the agreement. The primary contingency noted is the ability of either party to terminate the subaward with 30 days' notice.
Key Facts for Investor Verification
- Verify the total cumulative funding received to date under the four-year NIH Grant against the $45.1 million total award value.
- Confirm the status of the Expanded Access Program for CNM-Au8® and patient enrollment numbers for the ALS treatment.
- Review the company's most recent 10-K or 10-Q filings for current cash position and burn rate, as this 8-K does not provide liquidity data.
- Monitor the execution of the Year 3 subaward to ensure invoices are submitted and reimbursed as scheduled to maintain cash flow.